Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 1
Submit an article Journal homepage
197
Views
8
CrossRef citations to date
0
Altmetric
Review

Drug interactions with angiotensin receptor blockers

Steffen Böhler Technical University of Dresden, Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Fiedlerstrasse 27, D-01307 Dresden, Germany. [email protected]
,
David Pittrow Technical University of Dresden, Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Fiedlerstrasse 27, D-01307 Dresden, Germany. [email protected]
,
Peter Bramlage Technical University of Dresden, Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Fiedlerstrasse 27, D-01307 Dresden, Germany. [email protected]
&
Wilhelm Kirch Technical University of Dresden, Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Fiedlerstrasse 27, D-01307 Dresden, Germany. [email protected]
Pages 7-18 | Published online: 22 Apr 2005

Bibliographys

  • KEARNEY PM, WHELTON M, REYNOLDS K, WHELTON PK, HE J: Worldwide prevalence of hypertension. A systematic review. J. Hypertens. (2004) 22:11–18.
  • VASAN RS, BEISER A, SESHADRI S et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 287:1003–1010.
  • CHOBANIAN AV BAKRIS GL, BLACK HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report. /AMA (2003) 289:2560–2572.
  • •Recent US hypertension guidelines.
  • MATERSON BJ, REDA DJ, CUSHMAN WC et al.: Single-drug therapy for hypertension in men - a comparison of six antihypertensive agents with placebo. N Engl. J. Med. (1993) 328:914–921.
  • MATERSON BJ, REDA DJ, CUSHMAN WC: Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am. J. Hypertens. (1995) 8:189–192.
  • BLACK HR, ELLIOTT WJ, NEATON JD et al.: Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension (2001) 37:12–18.
  • CUSHMAN WC, FORD CE, CUTLER JA et al.: Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT). Clin. Hypertens. (2002) 4:393–404.
  • NICHOL MB, MARGOLIES JE, GILL MA: Factors associated with antihypertensive prescribing. Ann. Pharmacother. (1997) 31:154–159.
  • SEYMOUR RM, ROUTLEDGE PA: Important drug-drug interactions in the elderly. Drugs Aging (1998) 12:485–494.
  • BRAMLAGE P, SIEPMANN M, KIRCH W: Drug interactions in the elderly. Dtsch Med. Wochenschr. (2004) 129:895–900.
  • ••Detailed review of drug interactions in theelderly.
  • STEWART RB, COOPER JW: Polypharmacy in the aged. Practical solutions. Drugs Aging (1994) 4:449–461.
  • UNGER T, KASCHINA E: Drug interactions with ARBs: a comparison with other antihypertensives. Drug Sal' (2003) 26:707–720.
  • BEARD K: Adverse reactions as a cause of hospital admission in the aged. Drugs Aging (1992) 2:356–367.
  • BATES DW, SPELL N, CULLEN DJ et al.: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA (1997) 277:307–311.
  • LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279:1200–1205.
  • FLOCKHART DA, TANUS-SANTOS JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. (2002) 162:405–412.
  • ••Summary of important GYP-induceddrug interactions and cases that resulted in withdrawel from the market.
  • GROSSMAN E, MESSERLI FH, NEUTEL JM: Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch. Intern. Med. (2000) 160:1905–1911.
  • BURNIER M: Angiotensin II type 1 receptor blockers. Circulation (2001) 103:904–912.
  • KIRCH W, HORN B, SCHWEIZER J: Comparison of angiotensin II receptor antagonists. Eur. j Clin. Invest. (2001) 31:698–706.
  • GUIDELINES COMMITTEE: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011–1053.
  • •Recent European hypertension guidelines.
  • DZIELAK DJ: Comparative pharmacology of the angiotensin II receptor antagonists. Expert Opin. Investig. Drugs (1998) 7:741–751.
  • WEXLER RR, GREENLEE WJ, IRVIN JD et al.: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy./ Med. Chem. (1996) 39:625–656.
  • SLAUGHTER RL, EDWARDS DJ: Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. (1995) 29:619–624.
  • TAAVITSAINEN P, KIUKAANNIEMI K, PELKONEN 0: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol (2000) 56:135–140.
  • KAUKONEN KM, OLKKOLA KT, NEUVONEN PJ: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. j Clin. Pharmacol (1998) 53:445–449.
  • KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol Ther. (1997) 62:417–425.
  • FISCHER TL, PIEPER JA, GRAFF DW et al.: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol Ther. (2002) 72:238–246.
  • SCRIPTURE CD, PIEPER JA: Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. (2001) 40:263–281.
  • GOLDBERG MR, LO MW, DEUTSCH PJ, WILSON SE, MCWILLIAMS EJ, MCCREA JB: Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin. Pharmacol Ther. (1996) 59:268–274.
  • WILLIAMSON KM, PATTERSON JH, MCQUEEN RH, ADAMS KF Jr, PIEPER JA: Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin. Pharmacol Ther. (1998) 63:316–323.
  • SCHAEFER KL, PORTER JA: Angiotensin II receptor antagonists: the prototype losartan. Ann. Pharmacother. (1996) 30:625–636.
  • GOLDBERG MR, LO MW, BRADSTREET TE, RITTER MA, HOGLUND P: Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur. Clin. Pharmacol (1995) 49:115–119.
  • LILL J, BAUER LA, HORN JR, HANSTEN PD: Cyclosporin-drug interactions and the influence of patient age. Am. J. Health Syst. Pharm. (2000) 57:1579–1584.
  • SCHMIDT A, GRUBER U, BOHMIG G,KOLLER E, MAYER G: The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol. Dial. Transplant. (2001) 16:1034–1037.
  • DEL CASTILLO D, CAMPISTOL JM, GUIRADO Let al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int. (1998) 68:S135–S139.
  • ZAIDENSTEIN R, SOBACK S, GIPS M et al.: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther. DrugMonit. (2001) 23:369–373.
  • CHAWIA PS, KOCHAR MS: Effect of pain and nonsteroidal analgesics on blood pressure. WMJ(1999) 98:22–29.
  • CONLIN PR, MOORE TJ, SWARTZ SL et al.: Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension (2000) 36:461–465.
  • NAWARSKAS JJ, TOWNSEND RR, CIRIGLIANO MD, SPINLER SA: Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am. J. Hypertens. (1999) 12:784–789.
  • DE SMET M, SCHOORS DF, DE MEYER G et al.: Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br. J. Clin. Pharmacol (1995) 40:571–575.
  • KONG AN, TOMASKO L, WALDMAN SA et al.: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. (1995) 35:1008–1015.
  • MCCREA JB, LO MW, TOMASKO L et al.: Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. j Clin. Pharmacol (1995) 35:1200–1206.
  • RUILOPE LM, SIMPSON RL, TOH J, ARCURI KE, GOLDBERG Al, SWEET CS: Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press. (1996) 5:32–40.
  • YAMAMOTO T, MORIWAKI Y, TAKAHASHI S, TSUTSUMI Z, HADA T: Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J. Rheumatol (2000) 27:2232–2236.
  • SOFFER BA, WRIGHT JT Jr, PRATT JH,WIENS B, GOLDBERG Al, SWEET CS: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 26:112–117.
  • ALDERMAN M, AIYER KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. (2004) 20:369–379.
  • SHAHINFAR S, SIMPSON RL, CARIDES AD et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. (1999) 56:1879–1885.
  • BLANCHE P, RAYNAUD E, KEROB D, GALEZOWSKI N: Lithium intoxication in an elderly patient after combined treatment with losartan. Eur. J. Clin. Pharmacol (1997) 52:501.
  • COLUSSI DM, PARISOT C, ROSSOLINO ML, BRUNNER LA, LEFEVRE GY: Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist./ Clin. Pharmacol. (1997) 37:214–221.
  • WALDMEIER F, FLESCH G, MULLER P et al.: Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica (1997) 27:59–71.
  • LASSILA M, FINCKENBERG P, PERE AK et al.: Comparison of enalapril and valsartan in cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br. J. Pharmacol (2000) 130:1339–1347.
  • LEUNG M, REMICK RA: Potential drug interaction between lithium and valsartan. Clin. Psychopharmacol. (2000) 20:392–393.
  • JUURLINK DN, MAMDANI MM, KOPP A, ROCHON PA, SHULMAN KI, REDELMEIER DA: Drug-induced lithium toxicity in the elderly: a population-based study. J. Am. Geriatr. Soc. (2004) 52:794–798.
  • BINDSCHEDLER M, DEGEN P, FLESCH G, DE GASPARO M, PREISWERK G: Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur. Clin. Pharmacol (1997) 52:371–378.
  • SCHMIDT EK, ANTONIN KH, FLESCH G, RACINE-POON A:An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur. J. Clin. Pharmacol (1998) 53:451–458.
  • NO AUTHORS LISTED: Diovan® (valsartan). In: Physicians desk reference (Volume 55). Sifton DW (Ed.), Montvale (NJ), Medical Economics Co., Inc. (2001):2166–2167.
  • NODA M, SHIBOUTA Y, INADA Y et ell.:Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide All antagonist. Biochem. Pharmacol (1993) 46:311–318.
  • JONKMAN JH, VAN LIER JJ, VAN HEININGEN PN, LINS R, SENNEWALD R, HOGEMANN A: Pharmacokinetic drug interaction studies with candesartan cilexetil. J. Hum. Hypertens. (1997) 11:31–35.
  • NIEMEYER C, HASENFUSS G, WATS U, KNAUF H, SCHAFER-KORTING M, MUTSCHLER E: Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur. j Clin. PharmacoL (1983) 24:661–665.
  • EASTHOPE SE, JARVIS B: Candesartan cilexetil: an update of its use in essential hypertension. Drugs (2002) 62:1253–1287.
  • CAZAUBON C, GOUGAT J, BOUSQUET F et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist./ PharmacoL Exp. Ther. (1993) 265:826–834.
  • CHRISTOPHE B, LIBON R, CAZAUBON C, NISATO D, MANNING A. CHATELAIN P: Effects of irbesartan (51147436/ BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Eur. j Pharmacol. (1995) 281:161–171.
  • BRUNNER HR: The new angiotensin IIreceptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am. J. Hypertens. (1997) 10:311–317.
  • BOURRIE M, MEUNIER V BERGER Y, FABRE G: Role of cytochrome P4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. (1999) 27:288–296.
  • MANGOLD B, GIELSDORF W, MARINO MR: Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin. Eur. J. Clin. PharmacoL (1999) 55:593–598.
  • MARINO MR, VACHHARAJANI NN: Drug interactions with irbesartan. Clin. Pharmacoki net. (2001) 40:605–614.
  • MARINO MR, VACHHARAJANI NN, HADJILAMBRIS OW: Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J. Clin. PharmacoL (2000) 40:875–879.
  • KISTLER T, AMBUHL PM: Renal safety of combined cyclooxygenase-2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med. Wkly (2001) 131:193–198.
  • BLUM RA, KAZIERAD DJ, TENERO DM: A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy (1999) 19:79–85.
  • RUILOPE L, JAGER B, PRICHARD B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. (2001) 10:223–229.
  • BONATE PL, REITH K, WEIR S: Drug interactions at the renal level. Implications for drug development. Clin. Pharmacokinet. (1998) 34:375–404.
  • MARTIN DE, TOMPSON D, BOIKE SC et al.: Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br. J. Clin. PharmacoL (1997) 43:661–664.
  • KAZIERAD DJ, MARTIN DE, ILSON B et al.: Eprosartan does not affect the pharmacodynamics of warfarin. J. Clin. PharmacoL (1998) 38:649–653.
  • MARTIN DE, DECHERNEY GS, ILSON BE et al.: Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with Type II diabetes mellitus. J. Clin. PharmacoL (1997) 37:155–159.
  • TENERO DM, MARTIN DE, ILSON BE et al.: Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. Ann. Pharmacother. (1998) 32:304–308.
  • KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. PharmacoL Ther. (1997) 62:417–425.
  • MAILLARD MP, PERREGAUX C, CENTENO C et al.: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. PharmacoL Exp. Ther. (2002) 302:1089–1095.
  • STANGIER J, SU CA: Pharmacokinetics ofrepeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J. Clin. PharmacoL (2000) 40:1347–1354.
  • SHARPE M, JARVIS B, GOA KL: Telmisartan: a review of its use in hypertension. Drugs (2001) 61:1501–1529.
  • STANGIER J, SU CA, FRAUNHOFER A.TETZLOFF W: Pharmacokinetics of acetaminophen and ibuprofen when co-administered with telmisartan in healthy volunteers. J. Clin. PharmacoL (2000) 40:1338–1346.
  • STANGIER J, SU CA, HENDRIKS MGet al.: Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J. Clin. PharmacoL (2000) 40:1331–1337.
  • STANGIER J, SU CA, HENDRIKS MG et al.: The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J. Clin. PharmacoL (2000) 40:1373–1379.
  • DUNSELMAN PH: Effects of the replacement of the angiotensin-converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin-converting enzyme inhibition (REPLACE) investigators. Int. J. Cardiol. (2001) 77:131–138.
  • MIZUNO M, SADA T, IKEDA M et al.:Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. j PharmacoL (1995) 285:181–188.
  • KOIKE H, SADA T, MIZUNO M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J. Hypertens. Suppl. (2001) 19:3–14.
  • WARNER GT, JARVIS B: Olmesartan medoxomil. Drugs (2002) 62:1345–1353.
  • LAEIS P, PUCHLER K, KIRCH W: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. Hypertens. (2001) 19:21–32.
  • WRENGER E, MULLER R, MOESENTHIN M, WELTE T, FROLICH JC, NEUMANN KH: Interaction of spironolactone with ACE inhibitors or ARBs: analysis of 44 cases. Br. Med. J. (2003) 327:147–149.
  • AMBROSIONI E, BORGHI C, COSTA FV: Captopril and hydrochlorothiazide: rationale for their combination. Br. J. Clin. PharmacoL (1987) 23:43–50.
  • STEINESS E, WALDORFF S: Different interactions of indomethacin and sulindac with thiazides in hypertension. Br. Med. J. (1982) 285:1702–1703.
  • SHIONOIRI H: Pharmacokinetic drug interactions with ACE inhibitors. Clin. Pharmacokinet. (1993) 25:20–58.
  • FINLEY PR, O'BRIEN JG, COLEMAN RW: Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J. Clin. Psychopharmacol (1996) 16:68–71.
  • CAPPELLI A. PERICOT MOHR GL G, GALLELLI A et al.: Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure. J. Med. Chem. (2004) 47:2574–2586.
  • LIU YH, YANG XP, SHESELY EG, SANKEY SS, CARRETERO OA: Role of angiotensin II Type 2 receptors and kinins in the cardioprotective effect of angiotensin II Type 1 receptor antagonists in rats with heart failure. J. Am. Coll. Cardiol. (2004) 43:1473–1480.

Website

  • http://www.eudravigilance.org/human/ index.asp Eudra Vigilance: Pharmacovigilance in the European Economic Area (2004).
  • ••The future of adverse event reporting inEurope.
  • http://www.pharma.us.novartis.com/ product/pi/pdf/diovan.pdf Diovan®, valsartan (Novartis). Prescribing Information(2004).
  • http://www.who.int/whr/ 192002/en/ WORLD HEALTH REPORT 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization (2002).
  • •WHO report on cardiovascular risk worldwide.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.